XBiotech Inc

XBITNASDAQUSD
2.32 USD
0.03 (1.28%)AT CLOSE (11:59 AM EDT)
2.33
0.03 (1.08%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
2.33
0.03 (1.08%)
🟢Market: OPEN
Open?$2.37
High?$2.39
Low?$2.32
Prev. Close?$2.35
Volume?19.7K
Avg. Volume?41.7K
VWAP?$2.36
Rel. Volume?0.47x
Bid / Ask
Bid?$1.99 × 100
Ask?$2.70 × 100
Spread?$0.71
Midpoint?$2.35
Valuation & Ratios
Market Cap?71.6M
Shares Out?30.5M
Float?16.2M
Float %?53.2%
P/E Ratio?N/A
P/B Ratio?0.51
EPS?-$1.49
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?16.01Strong
Quick Ratio?16.01Strong
Cash Ratio?15.83Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A
P/B?
0.51CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
1.0CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
-32.5%WEAK
ROA?
-30.3%WEAK
Cash Flow & Enterprise
FCF?$-40209000
Enterprise Value?$-53904832
Related Companies
Loading...
News
Profile
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Employees
85
Market Cap
71.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-04-15
Address
5217 WINNEBAGO LANE
AUSTIN, TX 78744
Phone: 512-386-2900